More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, more delays, and more problems for you. But it doesn’t have to be that way.
When a clinical trial is approaching, you have timelines to meet.
You probably have a CRO to onboard.
You have multiple vendor systems to launch, IP to deliver, and sites to activate.
But as hard as you may work, it’s your sites that are under the most pressure.
**They are under increasing financial and resource constraints.
**Devoting enough time to your virtual and onsite visits is incredibly burdensome.
**Onsite work remains challenging with fears of the next COVID variant’s impact.
And most of all, clinical trials are more complex than ever – increasing the clinical and operational burden on site staff.
Since clinical trial sites are not created equal – how can you identify those most capable of accelerating enrollment and conducting the study while you remediate and upskill those more likely to struggle and encounter delays?
Fortunately, there is a critical change you can make during study startup to accelerate time to first patient enrolled while reducing the burden placed on your sites and trial team.
ArcheMedX is pleased to lead a webinar that discusses real clinical trial examples from emerging biotechs that will give you techniques to:
- Simplify your approach to getting sites trained on your protocol and critical study objectives – earlier and with better results
- Identify which sites are best prepared to screen and enroll and which sites require additional support and monitoring
- Tailor your SIVs and remediation so every site you activate is ready to enroll – fast – and with less time and effort
- Reduce the amount of time your team and sites spend during study startup – by 50%